The healthcare sector might not be at the forefront of exciting developments like artificial intelligence, but because good ...

However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a ...

Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...

The added benefit is that AbbVie is a "Dividend King," which means it has consistently paid and increased dividends for the ...

AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late-stage trials. The market reaction ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

AbbVie’s revenue was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.95 ...

AbbVie Inc. (NYSE:ABBV – Get Free Report)’s stock price shot up 0.1% during trading on Friday after Citigroup raised their price target on the stock from $215.00 to $226.00. Citigroup currently has a ...

With a current dividend yield of 3.2%, AbbVie Inc. ABBV was a key stock in the investor’s portfolio earning $4,800 per month. The stock has gained about 42% over the past year. AbbVie has raised ...